154 related articles for article (PubMed ID: 10445835)
1. Higher incidence of severe hypoglycaemia leading to hospital admission in Type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas.
Stahl M; Berger W
Diabet Med; 1999 Jul; 16(7):586-90. PubMed ID: 10445835
[TBL] [Abstract][Full Text] [Related]
2. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide.
Holstein A; Plaschke A; Egberts EH
Diabetes Metab Res Rev; 2001; 17(6):467-73. PubMed ID: 11757083
[TBL] [Abstract][Full Text] [Related]
3. Incidence of and risk factors for severe hypoglycaemia in treated type 2 diabetes mellitus patients in the UK--a nested case-control analysis.
Bruderer SG; Bodmer M; Jick SS; Bader G; Schlienger RG; Meier CR
Diabetes Obes Metab; 2014 Sep; 16(9):801-11. PubMed ID: 24612200
[TBL] [Abstract][Full Text] [Related]
4. Severe hypoglycaemia during treatment with sulphonylureas in patients with type 2 diabetes in the Capital Region of Denmark.
Pilemann-Lyberg S; Thorsteinsson B; Snorgaard O; Zander M; Vestergaard H; Røder ME
Diabetes Res Clin Pract; 2015 Nov; 110(2):202-7. PubMed ID: 26515912
[TBL] [Abstract][Full Text] [Related]
5. Severe hypoglycaemia leading to hospital admission in type 2 diabetic patients aged 80 years or older.
Greco D; Pisciotta M; Gambina F; Maggio F
Exp Clin Endocrinol Diabetes; 2010 Apr; 118(4):215-9. PubMed ID: 20072965
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes.
Monami M; Dicembrini I; Kundisova L; Zannoni S; Nreu B; Mannucci E
Diabetes Obes Metab; 2014 Sep; 16(9):833-40. PubMed ID: 24635837
[TBL] [Abstract][Full Text] [Related]
7. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents.
Holstein A; Plaschke A; Ptak M; Egberts EH; El-Din J; Brockmöller J; Kirchheiner J
Br J Clin Pharmacol; 2005 Jul; 60(1):103-6. PubMed ID: 15963101
[TBL] [Abstract][Full Text] [Related]
8. Drug-induced severe hypoglycaemia in Type 2 diabetic patients aged 80 years or older.
Greco D; Angileri G
Diabetes Nutr Metab; 2004 Feb; 17(1):23-6. PubMed ID: 15163121
[TBL] [Abstract][Full Text] [Related]
9. Long-acting sulfonylureas -- long-acting hypoglycaemia.
Veitch PC; Clifton-Bligh RJ
Med J Aust; 2004 Jan; 180(2):84-5. PubMed ID: 14723592
[No Abstract] [Full Text] [Related]
10. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis.
Salvo F; Moore N; Arnaud M; Robinson P; Raschi E; De Ponti F; Bégaud B; Pariente A
BMJ; 2016 May; 353():i2231. PubMed ID: 27142267
[TBL] [Abstract][Full Text] [Related]
11. Severe hypoglycemia is associated with antidiabetic oral treatment compared with insulin analogs in nursing home patients with type 2 diabetes and dementia: results from the DIMORA study.
Abbatecola AM; Bo M; Barbagallo M; Incalzi RA; Pilotto A; Bellelli G; Maggi S; Paolisso G;
J Am Med Dir Assoc; 2015 Apr; 16(4):349.e7-12. PubMed ID: 25669671
[TBL] [Abstract][Full Text] [Related]
12. Hypoglycaemia requiring medical assistance in patients with diabetes: a prospective multicentre survey in tertiary hospitals.
Liatis S; Mylona M; Kalopita S; Papazafiropoulou A; Karamagkiolis S; Melidonis A; Xilomenos A; Ioannidis I; Kaltsas G; Lanaras L; Papas S; Basagiannis C; Kokkinos A
Diabetes Metab; 2015 Apr; 41(2):126-31. PubMed ID: 25468446
[TBL] [Abstract][Full Text] [Related]
13. Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study.
van Dalem J; Brouwers MC; Stehouwer CD; Krings A; Leufkens HG; Driessen JH; de Vries F; Burden AM
BMJ; 2016 Jul; 354():i3625. PubMed ID: 27413017
[TBL] [Abstract][Full Text] [Related]
14. Access to emergency room for hypoglycaemia in people with diabetes.
Salutini E; Bianchi C; Santini M; Dardano A; Daniele G; Penno G; Miccoli R; Del Prato S
Diabetes Metab Res Rev; 2015 Oct; 31(7):745-51. PubMed ID: 26044573
[TBL] [Abstract][Full Text] [Related]
15. [Incidence of severe hypoglycemia in relation to metabolic control and patient knowledge].
Ratzmann KP; Schimke E
Med Klin (Munich); 1995 Oct; 90(10):557-61. PubMed ID: 7500918
[TBL] [Abstract][Full Text] [Related]
16. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia.
Holstein A; Plaschke A; Hammer C; Egberts EH
Eur J Clin Pharmacol; 2003 Jun; 59(2):91-7. PubMed ID: 12698302
[TBL] [Abstract][Full Text] [Related]
18. Sulfonylurea derivatives and risk of hypoglycaemia in type 2 diabetic patients.
Svěcený J; Jirušková J; Hrach K; Radovnická L; Laštůvka J
Vnitr Lek; 2020; 66(6):35-42. PubMed ID: 33380151
[TBL] [Abstract][Full Text] [Related]
19. The association between adherence to oral anti-diabetic drugs and hypoglycaemia in persons with Type 2 diabetes.
Quilliam BJ; Ozbay AB; Sill BE; Kogut SJ
Diabet Med; 2013 Nov; 30(11):1305-13. PubMed ID: 23586474
[TBL] [Abstract][Full Text] [Related]
20. Changes in incidence of severe hypoglycaemia in people with type 2 diabetes from 2006 to 2016: analysis based on health insurance data in Germany considering the anti-hyperglycaemic medication.
Müller N; Lehmann T; Klöss A; Günster C; Kloos C; Müller UA
Diabet Med; 2020 Aug; 37(8):1326-1332. PubMed ID: 32145093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
